Investor Relations Home

Profile
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries.
Stock Quote
IRIX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$5.51
Change (%) Stock is Up 0.06 (1.10%)
Volume87,754
Data as of 10/17/18 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
10/15/18IRIDEX Announces Appointment of Robert E. Grove, Ph.D. to its Board of Directors
MOUNTAIN VIEW, Calif., Oct. 15, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the appointment of Dr. Robert Grove to the Company’s Board of Directors effective October 15, 2018. Concurrently, Ann Rhoads will step down from the Board of Directors to focus attention on her new responsibility as Chief Financial Officer of Forty Seven Inc. “Bob is a perfect fit for our Board of Directors and will be an excellent addition,” said William M. Moore, Chairman and Chief E... 
Printer Friendly Version
09/14/18IRIDEX Announces Pricing of Public Offering of Common Stock
MOUNTAIN VIEW, Calif., Sept. 14, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ:IRIX) ("IRIDEX" or the "Company"), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, today announced the pricing of its underwritten public offering of 1,666,667 shares of its common stock at a price to the public of $6.00 per share.  In addition, the Company has granted the underwrit... 
Printer Friendly Version
09/13/18IRIDEX Announces Proposed Public Offering of Common Stock
MOUNTAIN VIEW, Calif., Sept. 13, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ:IRIX) ("IRIDEX" or the "Company"), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. IRIDEX also expects to grant the underwriters ... 
Printer Friendly Version
09/06/18IRIDEX Announces FDA Clearance to Introduce Updated TruFocus LIO Premiere™ Laser Accessory to the U.S. Market
MOUNTAIN VIEW, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the introduction of its updated TruFocus LIO Premiere™ laser accessory following U.S. Food and Drug Administration (FDA) 510(k) review and clearance.   The TruFocus LIO Premiere is a light combination and reflection viewing system used with IRIDEX retina laser systems and is worn on the physician’s head. The product combines a laser treatment beam from an IRIDEX laser source with the il... 
Printer Friendly Version
Primary IR Contact
Lynn Lewis or Leigh Salvo
Phone: (415) 937-5404
E-mail: investors@iridex.com


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.


logo aa0logo agslogo ascrslogo asrslogo esrs0logo euretina